Meister W
MMW Munch Med Wochenschr. 1981 Sep 18;123(38):1403-6.
In a recently published study, timolol lowered the overall mortality by 43% and the reinfarction rate by 37% during an average duration of treatment of 17 months after myocardial infarction. Although the timolol study is the best and most convincing of the post-infarction therapy studies yet presented, some important questions remain unanswered; in particular, the effect of other measures (eg the control of risk factors) is not clear. The future role of timolol will depend on further analysis of the study and on the definition of its significance as part of a comprehensive management plan of post-infarction patients.
在最近发表的一项研究中，噻吗洛尔在心肌梗死后平均17个月的治疗期间使总死亡率降低了43%，再梗死率降低了37%。尽管噻吗洛尔研究是目前已发表的心肌梗死后治疗研究中最好且最具说服力的，但一些重要问题仍未得到解答；特别是，其他措施（如危险因素的控制）的效果尚不清楚。噻吗洛尔未来的作用将取决于对该研究的进一步分析以及其作为心肌梗死后患者综合管理计划一部分的意义的界定。
